Research Progress of Shengjiangsan in Treating Systemic Inflammatory Response Syndrome
10.13422/j.cnki.syfjx.20201983
- VernacularTitle:升降散治疗全身炎症反应综合征的研究进展
- Author:
Yun-pu QIN
1
;
Ming-da BI
1
;
Shan-shan ZHANG
1
;
Yu HAN
1
;
Ji-hong FENG
2
Author Information
1. Tianjin University of Traditional Chinese Medicine（TCM）， Tianjin 300193， China
2. The Second Affiliated Hospital of Tianjin University of TCM， Tianjin 300150， China
- Publication Type:Research Article
- Keywords:
Shengjiangsan;
systemic inflammatory response syndrome;
sepsis;
pneumonia;
immune regulation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(23):187-192
- CountryChina
- Language:Chinese
-
Abstract:
Shengjiangsan was recorded in a medical book Treatise on Cold-induced Disorders and Plague written in the Qing Dynasty. This prescription， consisting of four drugs： Bombyx， cicada slough， Turmeric and Rhubarb， is simple but effective in regulating Qi and eliminating pathogenic factors. In recent years， the researches on the mechanism of this prescription have been continuously expanded and deepened. According to the collected data， Shengjiangsan is widely used in the treatment of various clinical diseases. The concept of systemic inflammatory response syndrome （SIRS） was first proposed in the 1990s， and it refers to the pathophysiological state caused by self-amplified cascade inflammatory response and inflammatory factor storm arising from infectious or non-infectious factors. In recent years， the treatment of SIRS has gradually become the current focus and hotspot. Patients with severe acute respiratory syndrome （SARS） and novel coronavirus pneumonia （COVID-19） often die from SIRS progression to multiple organ dysfunction syndrome （MODS） or even multiple organ failure （MOF）. Interleukin -1 receptor antagonist， anti-bradykinin， platelet activating factor receptor antagonist and other commonly used drugs in clinical treatment of SIRS have not achieved satisfactory results， so it is urgent to find drugs to improve SIRS status. Shengjiangsan is recommended as an initial prescription in traditional Chinese medicine diagnosis and treatment plan for SARS and COVID-19， and its antiviral effect may be related to preventing SIRS from transforming into MODS. Pharmacological studies have shown that Shengjiangsan can regulate the immune imbalance of SIRS to achieve a balance by intervening various inflammatory factors and their signaling pathways. At present， there are few reports on the treatment of SIRS with Shengjiangsan. Therefore， the theoretical analysis of Shengjiangsan and its clinical research and pharmacological mechanism in the treatment of SIRS are discussed here to broaden the thinking for clinical practice and experimental research.
